• PD 0332991: CDK4/6 Mechanism & Research Use

  2026-09-03

  PD 0332991, also called Palbociclib HCl, is a selective CDK4/6 inhibitor that suppresses Rb protein phosphorylation and promotes cell cycle G1 phase arrest. Product data support defined in vitro and mouse xenograft benchmarks, while patient-derived gastric cancer assembloid research shows why stromal context can alter drug-response interpretation.

• Oligo (dT) 25 Beads for mRNA Workflows

  2026-09-03

  Oligo (dT) 25 Beads streamline polyA-selected mRNA recovery from total RNA, cultured cells, and animal or plant tissues. Their magnetic format supports rapid purification, direct first-strand cDNA synthesis, and transcriptomic workflows such as the integrated RNA and metabolite analysis used to investigate cisplatin resistance.

• CBD Mechanisms in Orofacial Inflammatory Pain

  2026-09-02

  A 2026 Brain Research Bulletin study shows that cannabidiol reduces both sensory pain and pain-related emotional and cognitive deficits in mouse inflammatory pain models. Its key contribution is a multilevel mechanistic framework linking peripheral CB2 signaling, central endocannabinoid regulation, and serotonin dynamics in the central amygdala.

• Hydroxytyrosol for Nicotine-CKD Research

  2026-09-02

  Build a controlled kidney-cell workflow that tests whether Hydroxytyrosol can reduce nicotine-associated oxidative and inflammatory phenotypes without confusing antioxidant activity with nonspecific cytoprotection. The article translates a nicotine–chronic kidney disease mechanism review into practical dosing, controls, readouts, and troubleshooting decisions.

• Bafilomycin C1 in Translational Phenotypic Screening

  2026-09-01

  How V-ATPase inhibition can connect lysosomal mechanism, autophagy assays, and high-content translational screening—without confusing a useful perturbation tool with a clinical surrogate.

• Tolazoline: From Airway Nerves to β-Cell Assays

  2026-09-01

  Tolazoline is an α2-adrenergic receptor antagonist whose value depends on matching concentration, tissue model, and readout. This article develops an assay-centered framework linking airway nerve inhibition with insulin secretion modulation and β-cell potassium-channel biology.

• GSK-923295: CENP-E Inhibitor Workflows

  2026-08-31

  GSK-923295 enables controlled interrogation of CENP-E-dependent chromosome alignment, mitotic arrest, and tumor-cell response. This workflow-focused guide connects quantitative dosing with microscopy, cell-cycle, viability, and CTCF-centered comparative assays.

• Mitoxantrone Workflows for ABCG2 Resistance

  2026-08-30

  Turn Mitoxantrone’s topoisomerase II activity into reproducible oncology and antiviral research workflows. This guide pairs formulation control, apoptosis readouts, and ABCG2-aware accumulation assays to distinguish intrinsic drug response from transporter-mediated resistance.

• CAY10499 and the Lipid Logic of TAM Programming

  2026-08-29

  CAY10499 provides a mechanistic way to interrogate HSL, MGL, and FAAH activity alongside extracellular vesicle-driven macrophage programming. This thought-leadership guide connects lipid hydrolysis, ACLY-dependent immunometabolism, assay design, and translational strategy without overstating the current evidence.

• LIRP for Light-Controlled Gene Therapy

  2026-08-29

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic transgene activity at the translation stage. In mouse models, LIRP-based AAV systems enabled daylight-driven treatment and reversible interruption of gene therapy, highlighting a potential safety and dosing-control strategy for metabolic and retinal disease applications.

• IGFBP2–THBS1 Axis in GH Therapy for Idiopathic Short Stature

  2026-08-28

  The reference study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its perturbation experiments suggest that IGFBP2 is a functional mediator of the response, while also highlighting the need for validation beyond cell culture before clinical translation.

• Pioglitazone: A PPARγ Assay Design Guide

  2026-08-28

  Pioglitazone is a selective PPARγ agonist for connecting metabolic signaling with macrophage state and tissue inflammation. This guide translates recent DSS colitis evidence into practical assay decisions, controls, and interpretation strategies for translational research.

• Cefepime Beyond Coverage: A Translational Resistance Lens

  2026-08-27

  Cefepime (BMY-28142) can serve as more than a broad-spectrum comparator. By integrating cell-wall biology, resistance genotypes, plasmid mobility, CNS infection research, and safety-aware model design, translational teams can use this research reagent to build more predictive bacterial infection models.

• T-5224 Induces Ferroptosis in Multiple Myeloma

  2026-08-27

  The reference study links T-5224-mediated AP-1 inhibition to ferroptotic death of multiple myeloma cells through suppression of the PI3K/AKT pathway, reduced GPX4 and SLC7A11, and increased oxidative stress. Its rescue experiments with ferrostatin-1 and 740Y-P provide a mechanistic framework for studying AP-1 inhibition alongside bortezomib, while also highlighting the need for further validation beyond pharmacological evidence.

• L. gasseri, NR1I3, and E-Cadherin in Colitis

  2026-08-26

  Qian et al. show that Lactobacillus gasseri ATCC33323 reduces DSS-induced colitis in mice and identify an intestinal E-cadherin-centered mechanism involving NR1I3-dependent CDH1 regulation. The study is notable for combining probiotic treatment, barrier phenotyping, intestinal E-cadherin semiknockdown, transcriptional analysis, and in vitro validation to move beyond an association between microbiota and inflammation.

455 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page